Nitrous oxide toxicity is an increasingly important Emergency Medicine presentation. It may be missed because patients do not always regard nitrous oxide as a “drug”, and because neurological symptoms can be vague, progressive or initially attributed to anxiety, functional illness, alcohol, cannabis or other recreational substances.
For Final FRCEM candidates, the key is to recognise the pattern: unexplained neurological symptoms, possible functional vitamin B12 deficiency, and the need to treat before confirmatory tests return.
The guideline relates to unregulated recreational nitrous oxide use. It does not refer to Entonox use in clinical care or anaesthetic nitrous oxide use.
In the ED, nitrous oxide toxicity should be considered in any patient with otherwise unexplained neurological abnormalities, especially younger adults or patients with possible recreational drug exposure.
Poisoning should be considered whenever diagnostic uncertainty exists in an undifferentiated patient. This is especially important when symptoms are neurological, fluctuating, unexplained, or inconsistent with a single anatomical lesion.
In suspected poisoning, the ED approach should remain systematic:
The causative agent should not delay emergency treatment to stabilise airway, breathing, circulation or central nervous system function.
A toxidrome is a pattern of clinical features caused by a particular class of drug or chemical. Toxidromes can help narrow the differential and guide early treatment, particularly when the substance is unknown.
Common ED toxidromes include:
Toxidrome Typical clinical pattern
Anticholinergic | Agitation, tachycardia, mydriasis, dry warm skin, urinary retention
Sympathomimetic | Agitation, tachycardia, hypertension, sweating, mydriasis, seizures
Serotonergic | Altered mental state, autonomic instability, hyperreflexia, clonus
Cholinergic | Salivation, lacrimation, miosis, bradycardia, vomiting, weakness
Opioid | Reduced consciousness, respiratory depression, miosis
Sedative-hypnotic | Reduced consciousness, ataxia, dysarthria, nystagmus
Nitrous oxide toxicity may not present as a dramatic classic toxidrome. It often presents as a neurological syndrome, with sensory disturbance, gait difficulty, ataxia, weakness or neuropsychiatric change.
For SBA purposes, this makes it a subtle diagnosis.
Nitrous oxide oxidises cobalamin, making vitamin B12 functionally inactive. This matters because vitamin B12 is needed for normal myelin maintenance and neurological function.
The important exam trap is this:
Vitamin B12 levels may be normal.
This is because nitrous oxide does not necessarily destroy vitamin B12; it makes it biologically ineffective. Therefore, a normal serum B12 level does not exclude clinically significant nitrous oxide toxicity.
Nitrous oxide toxicity can present with a broad neurological and neuropsychiatric spectrum.
High-yield presenting features include:
A typical SBA stem may describe a young person with progressive tingling in the feet, difficulty walking, falls, poor balance, and recent use of balloons or canisters.
Nitrous oxide toxicity may also present with features consistent with vitamin B12 deficiency.
Look for:
However, absence of macrocytosis does not exclude the diagnosis, particularly early in the course or if neurological symptoms predominate.
Patients may not volunteer nitrous oxide use unless asked directly. They may describe it as:
A full drug and alcohol history is essential. The ED clinician should specifically ask about nitrous oxide because some patients may not consider it a drug.
The wider toxicology history should also include:
A negative initial drug history should not end the diagnostic process.
The majority of ED investigation is aimed at excluding alternative causes of neuropathy, myelopathy, confusion or weakness.
Useful investigations may include:
The key biochemical tests are:
These are markers of impaired cobalamin function and may be raised even when serum vitamin B12 is normal.
Emergency Departments should have systems in place to take samples for homocysteine and methylmalonic acid. Results may take several days, so local protocols should clearly define who owns and follows up delayed results.
This is a high-yield Final FRCEM management point.
If nitrous oxide toxicity is suspected, treatment should be started before the return of confirmatory diagnostic tests.
A suggested regimen is:
The rationale is that delayed treatment risks ongoing neurological injury, and diagnostic confirmation may not be available during the ED attendance.
Nitrous oxide toxicity can coexist with other toxicological or non-toxicological diagnoses. Escalate or broaden investigation if there is:
In unknown poisoning, repeated ECGs and blood gases may be needed because abnormalities can evolve. A patient presenting early may deteriorate later.
Most toxicology care in the ED is supportive, but supportive care must be active and structured.
Key priorities include:
For nitrous oxide toxicity specifically, the key treatment is vitamin B12 replacement, alongside investigation for alternative or additional causes.
Single-dose activated charcoal is considered for many oral poisonings if a potentially toxic amount of a charcoal-adsorbed substance has been ingested within the previous hour.
It is not the key treatment for nitrous oxide toxicity, because nitrous oxide exposure is inhalational rather than an acute tablet ingestion.
For SBA purposes, do not be distracted by generic poisoning treatments if the question clearly describes chronic or repeated nitrous oxide use with neurological features.
Patients with significant neurological features should be referred for ongoing care, usually involving acute medicine, neurology or a local pathway depending on the hospital.
Consider admission if there is:
Patients presenting with consequences of drug use should be offered referral to drug and alcohol liaison services.
Discharge is only appropriate when the patient is clinically stable, deterioration is not anticipated, cognition is at baseline, appropriate follow-up is arranged, and delayed results have clear ownership.
Incorrect. Nitrous oxide causes functional B12 deficiency, so serum B12 may be normal.
Incorrect. Treatment should start if the diagnosis is suspected.
Incorrect. Patients may have ataxia, motor deficits, urinary retention, erectile dysfunction, confusion or personality change.
Incorrect. Ask specifically about nitrous oxide, balloons and canisters.
Incorrect. Early recognition, correct investigations, B12 replacement, exclusion of alternative diagnoses and appropriate referral are required.
Incorrect. Nitrous oxide toxicity may present as progressive neurological dysfunction rather than a dramatic excitatory or inhibitory toxidrome.
A likely exam stem may describe:
A young adult presents with progressive tingling in both feet, difficulty walking, falls, reduced vibration or proprioception, normal or borderline B12, and recreational balloon use.
The best investigation may be:
Homocysteine and methylmalonic acid
The best treatment is:
Intramuscular vitamin B12 without waiting for results
The common trap is:
Normal serum B12 does not exclude nitrous oxide toxicity.
Think of nitrous oxide toxicity when there are:
Best ED actions:
Nitrous oxide toxicity causes functional vitamin B12 deficiency.
Normal B12 does not exclude it.
Raised homocysteine and methylmalonic acid support the diagnosis.
Treat suspected cases immediately with intramuscular vitamin B12 before confirmatory results return.
In the ED, combine toxicological pattern recognition with an ABCDE approach and early TOXBASE/NPIS support when the presentation is severe, unclear or evolving.